NUTEX HEALTH Announces Earnings Results for Q2 of FY2023

August 13, 2023

🌥️Earnings Overview

On August 9 2023, NUTEX HEALTH ($NASDAQ:NUTX) released their results for the second quarter of FY2023, which ended on June 30 2023. Total revenue amounted to USD 58.9 million, representing a 1.5% rise from the same quarter of the prior year. Net income was significantly higher than the -19.4 million reported in the same period the year before, coming in at USD -3.5 million.

Share Price

NUTEX HEALTH announced their earnings results for the second quarter of fiscal year 2023 on Wednesday. The stock opened at $0.3 and closed at $0.3, a 3.5% increase from its prior closing price of 0.3. NUTEX HEALTH has seen a steady rise in their stock prices since the beginning of this fiscal year, demonstrating the strength of their business and the confidence investors have in their product. In the second quarter, they reported a strong revenue increase from the prior year, contributing to their overall growth. This strong performance shows that NUTEX HEALTH is well-positioned for future success.

They continue to invest in research and development to bring innovative products to market. They also have plans to expand their global reach, with plans to move into new markets in the coming months. Overall, NUTEX HEALTH is proving their ability to remain successful and competitive in the health sector. With their continued commitment to innovation and expansion, they are well-poised to continue their growth and success in the coming fiscal year. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Nutex Health. More…

    Total Revenues Net Income Net Margin
    197.37 -435.65 -22.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Nutex Health. More…

    Operations Investing Financing
    -1.73 -6.5 -6.62
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Nutex Health. More…

    Total Assets Total Liabilities Book Value Per Share
    436.23 328.01 0.14
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Nutex Health are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    31.2% -222.4%
    FCF Margin ROE ROA
    -3.6% -296.2% -62.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we conducted a thorough analysis of NUTEX HEALTH‘s fundamentals to assess its risk rating. Our analysis of NUTEX HEALTH’s balance sheet, cashflow statement, and financial journal generated 3 risk warnings that potential investors should be aware of. We urge potential investors to register with us to learn more about the details of our warning. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    They are competing with other leading organizations in the sector, such as NDatalyze Corp, Achiko AG, and NeonMind Biosciences Inc, which are all bringing cutting-edge technology and products to the market. Together, these organizations are revolutionizing healthcare and creating solutions that will help improve the lives of patients around the world.

    – NDatalyze Corp ($OTCPK:NDATF)

    NDatalyze Corp is a data analytics and software development company that provides services to clients in the areas of predictive analytics, machine learning, cloud computing and data integration. The company’s market cap of 5.69M as of 2023 is relatively low compared to other companies in the industry. This is reflected in its Return on Equity (ROE) of -89.99%, indicating that the company is not generating an adequate return on its shareholders’ equity investments. Despite these negative figures, NDatalyze has continued to invest in its products and services, which are gaining traction in their respective markets.

    – Achiko AG ($OTCPK:ACHKF)

    Achiko AG is a Swiss-based technology company that focuses on providing solutions to the global transportation industry. The company has a market capitalization of 5.02M as of 2023, indicating that it is a relatively small company. Despite its size, Achiko AG has demonstrated strong financial performance, with a Return on Equity (ROE) of 62.69%. This indicates that the company is able to generate significant returns with its existing assets. The company’s impressive financial performance is a testament to its innovative solutions and commitment to customer satisfaction.

    – NeonMind Biosciences Inc ($OTCPK:NMDBF)

    NeonMind Biosciences Inc is a Canadian biotechnology company focused on the research and development of psychedelic-inspired products for mental health and wellness. With a market capitalization of 263.44k as of 2023, NeonMind Biosciences Inc is well-positioned to expand into new markets and drive further growth. This is further exemplified by the company’s impressive return on equity (ROE) of 107.62%. This suggests that the company is utilizing its resources efficiently and maximizing shareholder value in the process.


    NUTEX HEALTH has reported strong earnings for the second quarter of FY2023, with total revenue growing 1.5% year-over-year. Net income was significantly improved from the prior year, resulting in a stock price increase on the same day. Analysts have seen this as a positive sign for the company, and there is optimism that NUTEX HEALTH will continue to post solid earnings in the future. Investors should keep an eye out for any disclosures or updates that impact the company’s financial health, and do their own research before making any investment decisions.

    Recent Posts

    Leave a Comment